BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190813
DTEND;VALUE=DATE:20190816
DTSTAMP:20260515T001417
CREATED:20190530T091644Z
LAST-MODIFIED:20190530T091644Z
UID:20938-1565654400-1565913599@www.pharmajournalist.com
SUMMARY:B3DD Summit
DESCRIPTION:The Blood-Brain Barrier Delivery Summit (B3DD) is the industry’s first conference dedicated to addressing the translational challenges of effective and safe delivery of CNS drug candidates. \n \nWith an emphasis on biologics\, and built with the field’s leading minds from the likes of Biogen\, Genentech\, Armagen & Denali\, the B3DD Summit will unite over 60 industry stakeholders giving you the opportunity to develop new partnerships and build on existing relationships to ensure you have the connections to accelerate your drug’s development. \nSome of the highlights include: \n\nAssessing Microphysiological Models of the BBB – Biogen\nEmploying in vivo Microdialysis & Microperfusion Methods to Understand Brain Disposition of Biologics for the Treatment of CNS Disorders – AbbVie\nClinical Efficacy of Antibody-enzyme Fusion Proteins as Carrier Platform to Transport Lysosomal Enzymes Across the BBB for the Treatment of Mucopolysaccharidosis Type I\nPKPD of Different Therapeutic Modalities for CNS Indications – Genentech\nExplaining Clinical Failures – Is Efficacy or Delivery to Blame?- Merck\, Lundbeck\, AbbVie\n\nTo learn more about B3DD Summit\, and to register online\, visit https://ter.li/7vs04e
URL:https://www.pharmajournalist.com/event/b3dd-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190820
DTEND;VALUE=DATE:20190823
DTSTAMP:20260515T001417
CREATED:20190529T091738Z
LAST-MODIFIED:20190529T091738Z
UID:20911-1566259200-1566518399@www.pharmajournalist.com
SUMMARY:2nd Annual Hemophilia Drug Development Summit
DESCRIPTION:Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies\, the 2nd Annual Hemophilia Drug Development Summit\, once again unites leading pharma\, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders. \n \nAttend the 2nd Hemophilia Drug Development Summit to identify novel drug development strategies and overcome the shared translational\, clinical development and delivery challenges to dramatically improve patient outcomes. \nSounds interesting? Find out more – get free event brochure here: https://ter.li/4snxn9
URL:https://www.pharmajournalist.com/event/hemophilia-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190822
DTEND;VALUE=DATE:20190824
DTSTAMP:20260515T001417
CREATED:20190531T125458Z
LAST-MODIFIED:20190531T125545Z
UID:21020-1566432000-1566604799@www.pharmajournalist.com
SUMMARY:4th Annual Medical Device Regulatory and Quality Summit 2019
DESCRIPTION:4th Annual Medical Device Regulatory and Quality Summit 2019 will create a platform for regulators\, industry stalwarts to come under one roof to discuss and share ideas that would not only benefit their organisations\, but at large the industry as well. The 4th Annual Medical Device Regulatory and Quality Summit 2019 will review the evolving regulations\, their impact on the industry as well as take an in depth look into areas of quality control and assurance. \n \nTo learn more about this event\, and to register online\, visit http://bit.ly/2MgH15z
URL:https://www.pharmajournalist.com/event/4th-annual-medical-device-regulatory-and-quality-summit-2019/
LOCATION:New Delhi\, India
ORGANIZER;CN="Inventicon Business Intelligence":MAILTO:pooja.mishra@inventicon.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190827
DTEND;VALUE=DATE:20190830
DTSTAMP:20260515T001417
CREATED:20180531T135859Z
LAST-MODIFIED:20190430T084109Z
UID:16049-1566864000-1567123199@www.pharmajournalist.com
SUMMARY:3rd Annual IPF Summit
DESCRIPTION:The IPF Summit focuses exclusively on closing the translational gap between preclinical predictability and clinical attrition to accelerate the development of truly curative idiopathic pulmonary fibrosis (IPF) therapeutics. \n \nWith the 2019 conference expanding upon an even greater breadth and depth of content\, you’ll hear three days of unrivalled scientifically driven and case-study based analysis and discussion\, as together leading academia and biopharma advance the IPF drug development frontier. \nLast year\, over 90 of IPF’s expert drug developers came together to advance the standardisation of imaging\, share clinical insights\, and evaluate better recapitulating disease physiology in vitro exclusively for IPF: \n“This was a superb meeting combining several emerging themes in IPF therapies and a dynamic mix of formal presentations with impromptu networking. All the speakers were excellent\, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job!” \nCeders-Sinai Medical Center \nWith the incredible breakthrough success of drugs now in our arsenal for slowing IPF disease progression\, the increasing importance of identifying genetic mechanisms\, closing the translational gap between preclinical and clinical results\, and developing candidates to reverse fibrosis have opened up further challenges within IPF drug development. \nJoin “part 3” as the IPF community converges again to: \n\nAnalyze the latest understanding of IPF pathology for improved target validation of next generation therapeutics and the potential to promote tissue regeneration to achieve reversal of fibrosis\nCritically discuss how to design the next generation of phase III clinical trials for candidate success in light of a current standard of care\nOutline progressions in the standardization of imaging and advancements of biomarkers to improve translational success and more confident diagnosis of patients\n\nTo learn more about 3rd Annual IPF Summit and to register online\, visit https://ter.li/i81anp \nContact \nEmail – info@hansonwade.com\nPhone – +1 415 735 3289
URL:https://www.pharmajournalist.com/event/ipf-summit/
LOCATION:Sheraton San Diego Hotel & Marina\, 1380 Harbor Island Drive\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR